MedPath

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

Not Applicable
Withdrawn
Conditions
Exercise-induced Bronchospasm
Interventions
Other: Placebo
Dietary Supplement: Vitamin C
Registration Number
NCT03610932
Lead Sponsor
University of Kansas Medical Center
Brief Summary

The purpose of this research is to assess the association between diet and pulmonary function during standardized EIB testing. Determine the effect of Vitamin C supplementation on airway inflammatory markers and bronchoconstriction after a standardized EIB test compared to usual diet and placebo control.

Detailed Description

This study will use a double-blind, randomized, cross-over design with subjects serving as their own controls. This study will be conducted over a consecutive five-week period.

All subjects will be asked to discontinue taking their short- and long-acting beta-agonist medication 12 and 24 hours respectively prior to data collection. Also, all subjects will be asked to refrain from caffeine, physical activity, and NSAID use 24 hours prior to testing. In addition all subjects will be asked to abstain from taking any vitamin supplement during the course of the study.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Student or student-athlete who has tested positive for EIB
  • Able to communicate in English
Exclusion Criteria
  • Forced expiratory volume in 1 second (FEV1) < 70% of predicted, cardiac history,
  • Current respiratory infection
  • > 10 pack year history of smoking
  • Pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboParticipants will ingest a matched capsule for size and color to the Vitamin C supplement.
Vitamin CVitamin CParticipants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
Primary Outcome Measures
NameTimeMethod
Change in airway inflammatory biomarkersChange from Baseline to End of Week 5

Urinary concentrations of cysteine leukotrienes (LTC4-LTE4), prostaglandin (9α,11β-PGF2), and creatinine will be measured.

Secondary Outcome Measures
NameTimeMethod
Dietary Intake QuestionnaireChange from Baseline to End of Week 5

Baseline dietary intake will be assessed by the National Cancer Institute's Diet Health Questionnaire II (DHQ II). It consists of 134 food items and 8 dietary supplement questions. It calculates the Healthy Eating Index (HEI) that is a measure of diet quality. Scores range from 0 to 100. The higher the score the healthier the diet.

Pulmonary function testingChange from Baseline to End of Week 5

The outcome will measure the change in the first second of forced expiration (FEV1).

Cardiorespiratory FitnessBaseline

Cardiorespiratory fitness will be assessed during the EIB test by an integrated metabolic measurement system that will be used for measurement of oxygen consumption. The metabolic cart will be set to produce a 15-second average of the data collected during gas analyses for all tests.

Change in quality of life: asthma quality of life questionnaire (AQLQ)Change from Baseline to End of Week 5

Asthma specific quality of life will be measured by the validated asthma quality of life questionnaire (AQLQ). The AQLQ includes 32 separate responses within 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). Each response option is based on a 7-point scale, where 1 represents maximal impairment and 7 indicates no impairment. Scores for the four domains and overall score are computed as averages of the item scores. The minimal important difference for overall and each domain, has been determined to be a change in score of 0.5 per item.

Trial Locations

Locations (1)

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath